Frontiers in Immunology has organized a series of Research Topics which aim to promote debate or to change the perspective on unsettled clinical or experimental research in various areas of the field of immunology.
To provide a critical evaluation of the state of research in the field of "Immune checkpoint inhibitors for cancer treatment", leading experts have been invited by our Topic Editors to contribute their thoughts and perspectives on current challenges, latest discoveries, recent advances, and future perspectives in the field.
This Research Topic solicits the submission of Opinion and Perspective articles that provide editorialized analysis related to the field of "Immune checkpoint inhibitors for cancer treatment" by established researchers in the field.
Please note, contributions to this article collection are by invitation only. Please inform the Editorial Office at immunology.submissions@frontiersin.org once you are prepared to submit.
Topic Editor Sara Colombetti is employed by F. Hoffman-La Roche. The other Topic Editors declare no competing interests.
Frontiers in Immunology has organized a series of Research Topics which aim to promote debate or to change the perspective on unsettled clinical or experimental research in various areas of the field of immunology.
To provide a critical evaluation of the state of research in the field of "Immune checkpoint inhibitors for cancer treatment", leading experts have been invited by our Topic Editors to contribute their thoughts and perspectives on current challenges, latest discoveries, recent advances, and future perspectives in the field.
This Research Topic solicits the submission of Opinion and Perspective articles that provide editorialized analysis related to the field of "Immune checkpoint inhibitors for cancer treatment" by established researchers in the field.
Please note, contributions to this article collection are by invitation only. Please inform the Editorial Office at immunology.submissions@frontiersin.org once you are prepared to submit.
Topic Editor Sara Colombetti is employed by F. Hoffman-La Roche. The other Topic Editors declare no competing interests.